SCHEMBL20121187

SCHEMBL20121187

Cc1nn2cc(-c3ccn(C(=O)OCc4ccccc4)n3)nc2s1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.52
SMN1; SMN2 Q16637 6/20 0.52
TP53 P04637 6/20 0.52
NPC1 O15118 5/20 0.52
NFKB1 P19838 2/20 0.52
NFKB2 Q00653 2/20 0.52
RELA Q04206 2/20 0.52
ALOX15 P16050 2/20 0.52
KDM4E B2RXH2 1/20 0.50
HSD17B10 Q99714 1/20 0.50
F2RL3 Q96RI0 8/20 0.42
MAPT P10636 3/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
JMJD6 Q6NYC1 1/20 0.40
PKM P14618 1/20 0.39
RECQL P46063 1/20 0.39
TSHR P16473 1/20 0.38
TPH1 P17752 1/20 0.37
TPH2 Q8IWU9 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29010239 0.76 SCN4A (0.48) RAB9ASMN1; SMN2NPC1NFKB1NFKB2
SCHEMBL20181866 0.74 ALDH1A1 (0.49) RAB9ASMN1; SMN2NPC1KDM4EMAPT
SCHEMBL21187190 0.71 ALDH1A1 (0.45) RAB9ASMN1; SMN2NPC1MEN1KMT2A
SCHEMBL27812967 0.71 KMT2A (0.50) RAB9ASMN1; SMN2NPC1KDM4EMAPT
SCHEMBL29010226 0.70 PPARG (0.45) RAB9ASMN1; SMN2NPC1MAPTJMJD6
SCHEMBL25933306 0.70 ALDH1A1 (0.46) RAB9ASMN1; SMN2NPC1MEN1KMT2A
SCHEMBL20173269 0.69 HTR2C (0.46) RAB9ASMN1; SMN2NPC1MEN1KMT2A
SCHEMBL20675615 0.68 ALDH1A1 (0.47) RAB9ASMN1; SMN2NPC1MAPTMEN1
SCHEMBL23657842 0.68 SMN1; SMN2 (1.00) RAB9ASMN1; SMN2TP53NPC1NFKB1
SCHEMBL20471120 0.66 ALDH1A1 (0.45) RAB9ASMN1; SMN2NPC1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9963466-B2 Substituted 5-membered heterocyclic analogs as protease activated receptor 4 (PAR-4) antagonists VANDERBILT UNIVERSITY (US) 2018-05-08 US disclosed